US Patent

US7645789 — Indole derivatives as CFTR modulators

Composition of Matter · Assigned to Vertex Pharmaceuticals Inc · Expires 2027-05-01 · 1y remaining

Vulnerability score 5/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of indole derivatives that can modulate the CFTR protein, useful for treating diseases mediated by ABC transporters.

USPTO Abstract

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Drugs covered by this patent

Patent Metadata

Patent number
US7645789
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-05-01
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.